

# Giancarlo Comi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5740539/giancarlo-comi-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

361  
papers

28,388  
citations

76  
h-index

162  
g-index

388  
ext. papers

34,313  
ext. citations

7.9  
avg, IF

6.67  
L-index

#	Paper	IF	Citations
361	Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	4
360	Comparing natural history of early and late onset pediatric multiple sclerosis.. <i>Annals of Neurology</i> , <b>2022</b> ,	9.4	2
359	COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	17
358	Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder. <i>Pattern Recognition</i> , <b>2022</b> , 123, 108403	7.7	2
357	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 61, 103757	4	0
356	Visual Evoked Potentials to Monitor Myelin Cuprizone-Induced Functional Changes.. <i>Frontiers in Neuroscience</i> , <b>2022</b> , 16, 820155	5.1	0
355	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.. <i>Neurology</i> , <b>2022</b> , 98, e1626-e1636	6.5	0
354	Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach-perspectives from the International Progressive MS Alliance.. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2022</b> , 8, 20552173221099181	2	
353	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 103909	4	0
352	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , <b>2021</b> ,	6	1
351	Apparatus design and behavioural testing protocol for the evaluation of spatial working memory in mice through the spontaneous alternation T-maze. <i>Scientific Reports</i> , <b>2021</b> , 11, 21177	4.9	6
350	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> , 97, e1870-e1885	6.5	50
349	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study. <i>Neurology</i> , <b>2021</b> ,	6.5	4
348	Repetitive Transcranial Magnetic Stimulation With H-Coil Coupled With Cycling for Improving Lower Limb Motor Function After Stroke: An Exploratory Study. <i>Neuromodulation</i> , <b>2021</b> , 24, 916-922	3.1	2
347	Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1222-1229	5	0
346	DOP53 Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, Ulcerative Colitis, and Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S088-S089	1.5	0
345	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	3

344	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 51, 102844	4	3
343	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2021</b> , 78, 726-735	17.2	4
342	Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?. <i>Expert Review of Neurotherapeutics</i> , <b>2021</b> , 21, 21-34	4.3	4
341	Role of B Cells in Multiple Sclerosis and Related Disorders. <i>Annals of Neurology</i> , <b>2021</b> , 89, 13-23	9.4	38
340	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 430-438	5	1
339	Multiple Sclerosis Data Alliance - A global multi-stakeholder collaboration to scale-up real world data research. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 47, 102634	4	5
338	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 48, 102673	4	3
337	Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 347-359	5	24
336	The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 331-346	5	16
335	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2021</b> , 14, 17562864211019574	6.6	9
334	Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> ,	6.5	11
333	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , <b>2021</b> , 89, 780-789	9.4	189
332	Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis. <i>Annals of Neurology</i> , <b>2021</b> , 90, 253-265	9.4	2
331	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211035318	5	21
330	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 1738-1744	5.3	36
329	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 3722-3730	6	2
328	CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211032803	5	3
327	The 4-Hole-Board Test for Assessment of Long-Term Spatial Memory in Mice. <i>Current Protocols</i> , <b>2021</b> , 1, e228		1

326	Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies. <i>Advances in Therapy</i> , <b>2021</b> , 38, 4975-4985	4.1	2
325	Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2021</b> , 7, 2055217321990852	2	1
324	Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 46, 102572	4	13
323	The window of opportunity for treatment of progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , <b>2020</b> , 33, 262-270	7.1	14
322	Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , <b>2020</b> , 9, 443-457	4.6	4
321	Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. <i>Neurological Sciences</i> , <b>2020</b> , 41, 1647-1650	3.5	31
320	Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patient. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 41, 102061	4	2
319	Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. <i>Neurological Sciences</i> , <b>2020</b> , 41, 2843-2851	3.5	4
318	Human-Centered Design Strategies for Device Selection in mHealth Programs: Development of a Novel Framework and Case Study. <i>JMIR MHealth and UHealth</i> , <b>2020</b> , 8, e16043	5.5	11
317	Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19. <i>Journal of Medical Internet Research</i> , <b>2020</b> , 22, e19992	7.6	70
316	Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. <i>Drug Safety</i> , <b>2020</b> , 43, 635-643	5.1	7
315	Large vessel occlusion stroke due to dislodged aortic valve calcification revealed by imaging and histopathology. <i>Journal of the Neurological Sciences</i> , <b>2020</b> , 408, 116573	3.2	1
314	Italian consensus on treatment of spasticity in multiple sclerosis. <i>European Journal of Neurology</i> , <b>2020</b> , 27, 445-453	6	9
313	A new electrophysiological non-invasive method to assess retinocortical conduction time in the Dark Agouti rat through the simultaneous recording of electroretinogram and visual evoked potential. <i>Documenta Ophthalmologica</i> , <b>2020</b> , 140, 245-255	2.2	1
312	Upper limb motor evoked potentials as outcome measure in progressive multiple sclerosis. <i>Clinical Neurophysiology</i> , <b>2020</b> , 131, 401-405	4.3	7
311	Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis. <i>BMC Neurology</i> , <b>2020</b> , 20, 364	3.1	1
310	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , <b>2020</b> , 19, 988-997	24.1	28
309	COVID-19 in people with multiple sclerosis: A global data sharing initiative. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1157-1162	5	34

308	Teaching NeuroImages: Osteolytic intraosseous meningioma causing transcalvarial herniation. <i>Neurology</i> , <b>2020</b> , 95, e1110-e1111	6.5	
307	Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation. <i>Molecules</i> , <b>2020</b> , 25,	4.8	1
306	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 546-557	59.2	132
305	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , <b>2020</b> , 143, 2637-2652	11.2	22
304	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. <i>Journal of the Neurological Sciences</i> , <b>2020</b> , 417, 117064	3.2	0
303	Neuro-Retina Might Reflect Alzheimer's Disease Stage. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 77, 1455-1468	4.8	4
302	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , <b>2020</b> , 143, 3013-3024	11.2	20
301	Functional evolution of visual involvement in experimental autoimmune encephalomyelitis.. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2020</b> , 6, 2055217320963474	2	1
300	Structural connectivity in multiple sclerosis and modeling of disconnection. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 220-232	5	15
299	Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 233-244	5	9
298	Changes in functional and structural brain connectome along the Alzheimer's disease continuum. <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 230-239	15.1	37
297	Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 208-217	6.4	16
296	Leukocyte Counts and Ratios Are Predictive of Stroke Outcome and Hemorrhagic Complications Independently of Infections. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 201	4.1	15
295	Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. <i>Journal of Neurology</i> , <b>2020</b> , 267, 2272-2280	5.5	15
294	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , <b>2019</b> , 18, 1009-1020	24.1	96
293	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , <b>2019</b> , 18, 1021-1033	24.1	98
292	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. <i>Journal of Neurology</i> , <b>2019</b> , 266, 3098-3107	5.5	1
291	Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 29, 168-174	4	54

290	Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 33, 75-77	4	8
289	Expanding the spectrum of genes responsible for hereditary motor neuropathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 1171-1179	5.5	19
288	Engaging across dimensions of diversity: A cross-national perspective on mHealth tools for managing relapsing remitting and progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 32, 123-132	4	16
287	Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy". <i>Annals of Neurology</i> , <b>2019</b> , 86, 324	9.4	2
286	Concurrence of NMOSD and ALS in a patient with hexanucleotide repeat expansions of C9orf72. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , <b>2019</b> , 20, 449-452	3.6	1
285	Multispectral MRI with Dual Fluorinated Probes to Track Mononuclear Cell Activity in Mice. <i>Radiology</i> , <b>2019</b> , 291, 351-357	20.5	22
284	Survival prediction models in motor neuron disease. <i>European Journal of Neurology</i> , <b>2019</b> , 26, 1143-11526		11
283	Functional and structural plasticity following action observation training in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1472-1487	5	17
282	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1255-1262	5	24
281	Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 968-979	5	8
280	Emotional outcomes in clinically isolated syndrome and early phase multiple sclerosis: a systematic review and meta-analysis. <i>Journal of Psychosomatic Research</i> , <b>2019</b> , 124, 109761	4.1	7
279	Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e591	9.1	6
278	The CSF p-tau181/A $\beta$ 2 Ratio Offers a Good Accuracy "In Vivo" in the Differential Diagnosis of Alzheimer's Dementia. <i>Current Alzheimer Research</i> , <b>2019</b> , 16, 587-595	3	13
277	No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon $\beta$ 1a. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 39, 101891	4	1
276	Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. <i>Annals of Neurology</i> , <b>2019</b> , 85, 606-610	9.4	23
275	Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , <b>2019</b> , 18, 155-164	24.1	36
274	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , <b>2019</b> , 40, 155-165	3.5	42
273	Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 29, 157-167	4	65

272	Added value of multimodal MRI to the clinical diagnosis of primary progressive aphasia variants. <i>Cortex</i> , <b>2019</b> , 113, 58-66	3.8	4
271	Brain and cord imaging features in neuromyelitis optica spectrum disorders. <i>Annals of Neurology</i> , <b>2019</b> , 85, 371-384	9.4	42
270	Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. <i>Neurology</i> , <b>2019</b> , 92, e733-e741	6.5	30
269	The Multiple Sclerosis Care Unit. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 627-636	5	37
268	Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 28, 57-59	4	1
267	Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 204-216	5	16
266	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 565-573	5	4
265	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 399-407	5	20
264	Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 801-810	5	11
263	Cognitive reserve, cognition, and regional brain damage in MS: A 2 -year longitudinal study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 372-381	5	26
262	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 819-827	5	31
261	Cervical Cord T1-weighted Hypointense Lesions at MR Imaging in Multiple Sclerosis: Relationship to Cord Atrophy and Disability. <i>Radiology</i> , <b>2018</b> , 288, 234-244	20.5	28
260	Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2018</b> , 11, 1756285617753365	6.6	38
259	ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , <b>2018</b> , 25, 215-237	6	96
258	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 96-120	5	286
257	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. <i>Lancet Neurology</i> , <b>2018</b> , 17, 133-142	24.1	66
256	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , <b>2018</b> , 17, 162-173	24.1	2419
255	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2018</b> , 4, 2055217318760642	2	19

254	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet, The</i> , <b>2018</b> , 391, 1263-1273	40	422
253	Bi-hemispheric repetitive transcranial magnetic stimulation for upper limb motor recovery in chronic stroke: A feasibility study. <i>Brain Stimulation</i> , <b>2018</b> , 11, 932-934	5.1	3
252	Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 167-174	5	14
251	The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 535-539	5	11
250	Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 459-471	5	71
249	Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1183-1195	5	30
248	Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 902-907	5	3
247	Fast progressive lower motor neuron disease is an ALS variant: A two-centre tract of interest-based MRI data analysis. <i>NeuroImage: Clinical</i> , <b>2018</b> , 17, 145-152	5.3	25
246	Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1594-1604	5	140
245	Neuromyelitis optica spectrum disorder and multiple sclerosis in a Sardinian family. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 25, 73-76	4	3
244	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. <i>Acta Neurologica Scandinavica</i> , <b>2018</b> , 138, 447-453	3.8	2
243	Digital epidemiology confirms a latitude gradient of MS in France. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 20, 129-131	4	5
242	Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood. <i>Journal of the Neurological Sciences</i> , <b>2018</b> , 384, 58-60	3.2	1
241	Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients. <i>Neurological Sciences</i> , <b>2018</b> , 39, 373-376	3.5	7
240	040 An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, A17.1-A17	5.5	
239	Letter to the Editor Regarding: A Comprehensive Review on Copemyl. <i>Neurology and Therapy</i> , <b>2018</b> , 7, 385-390	4.6	1
238	The role of clinical and neuroimaging features in the diagnosis of CADASIL. <i>Journal of Neurology</i> , <b>2018</b> , 265, 2934-2943	5.5	15
237	039 Rates of lymphopenia in years 1-4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, A16.2-A16	5.5	1



236	067 Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, A27.2-A28	5.5	
235	Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 577-587	5	13
234	Subcutaneous interferon $\beta$ 1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 285-294	5.5	23
233	The first year after diagnosis: psychological impact on people with multiple sclerosis. <i>Psychology, Health and Medicine</i> , <b>2017</b> , 22, 1063-1071	2.1	17
232	Typical and atypical pathology in primary progressive aphasia variants. <i>Annals of Neurology</i> , <b>2017</b> , 81, 430-443	9.4	192
231	Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1864-1874	5	33
230	Evaluation of an optimized [ F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders. <i>European Journal of Neurology</i> , <b>2017</b> , 24, 687-e26	6	29
229	DT MRI microstructural cortical lesion damage does not explain cognitive impairment in MS. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1918-1928	5	7
228	Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1558-1561	5	2
227	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , <b>2017</b> , 81, 729-739	9.4	26
226	Structural brain abnormalities in patients with vestibular migraine. <i>Journal of Neurology</i> , <b>2017</b> , 264, 295-303	9.3	28
225	Structural and functional brain signatures of C9orf72 in motor neuron disease. <i>Neurobiology of Aging</i> , <b>2017</b> , 57, 206-219	5.6	35
224	Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes. <i>Acta Neurologica Scandinavica</i> , <b>2017</b> , 136, 454-461	3.8	15
223	Moyamoya disease mimicking the first attack of multiple sclerosis. <i>Journal of Neurology</i> , <b>2017</b> , 264, 1005-1007	5.5	2
222	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 221-234	59.2	858
221	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 209-220	59.2	880
220	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). <i>Journal of Neurology</i> , <b>2017</b> , 264, 2436-2449	5.5	35
219	Brain network connectivity differs in early-onset neurodegenerative dementia. <i>Neurology</i> , <b>2017</b> , 89, 1764-1772	5.3	53

218	Cerebrospinal Fluid Amyloid- $\beta$ 2, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 60, 183-200	4.3	25
217	'Progressive MS - macro views': The need for novel clinical trial paradigms to enable drug development for progressive MS. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1649-1655	5	3
216	Fluid biomarker and electrophysiological outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1600-1613	5	22
215	The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2017</b> , 3, 2055217317732802	2	17
214	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. <i>Brain</i> , <b>2017</b> , 140, 2814-2819	11.2	38
213	MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. <i>Neurology</i> , <b>2017</b> , 89, 1265-1273	6.5	9
212	Weight gain after subthalamic nucleus deep brain stimulation in Parkinson's disease is influenced by dyskinesias' reduction and electrodes' position. <i>Neurological Sciences</i> , <b>2017</b> , 38, 2123-2129	3.5	12
211	Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. <i>Drugs</i> , <b>2017</b> , 77, 1755-1768	12.1	33
210	Structural connectivity-defined thalamic subregions have different functional connectivity abnormalities in multiple sclerosis patients: Implications for clinical correlations. <i>Human Brain Mapping</i> , <b>2017</b> , 38, 6005-6018	5.9	26
209	Multimodal structural MRI in the diagnosis of motor neuron diseases. <i>NeuroImage: Clinical</i> , <b>2017</b> , 16, 240-247	5.3	40
208	Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice. <i>Journal of the Neurological Sciences</i> , <b>2017</b> , 383, 166-168	3.2	20
207	Pediatric versus adult MS: similar or different?. <i>Multiple Sclerosis and Demyelinating Disorders</i> , <b>2017</b> , 2,	0	23
206	Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. <i>Neurological Sciences</i> , <b>2017</b> , 38, 361-364	3.5	5
205	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. <i>Neurological Sciences</i> , <b>2017</b> , 38, 53-59	3.5	22
204	Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1194-1203	5	38
203	Brain plasticity in Parkinson's disease with freezing of gait induced by action observation training. <i>Journal of Neurology</i> , <b>2017</b> , 264, 88-101	5.5	60
202	Action observation training modifies brain gray matter structure in healthy adult individuals. <i>Brain Imaging and Behavior</i> , <b>2017</b> , 11, 1343-1352	4.1	6
201	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 257-266	1.2	24

200	Mapping face encoding using functional MRI in multiple sclerosis across disease phenotypes. <i>Brain Imaging and Behavior</i> , <b>2017</b> , 11, 1238-1247	4.1	2
199	Evolving concepts in the treatment of relapsing multiple sclerosis. <i>Lancet, The</i> , <b>2017</b> , 389, 1347-1356	4.0	185
198	The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 433	4.1	41
197	Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. <i>International Journal of MS Care</i> , <b>2017</b> , 19, 16-24	2.3	13
196	Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients. <i>Scientific Reports</i> , <b>2017</b> , 7, 40136	4.9	27
195	Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 247-255	4.1	19
194	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 468-75	5.5	109
193	Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 628-40	5	20
192	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 511-9	5	64
191	Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 292-301	5	13
190	Optic neuritis in multiple sclerosis: Looking from a patient's eyes. <i>Neurology</i> , <b>2016</b> , 87, 338-9	6.5	0
189	Amyloid- $\beta$ deposition and regional grey matter atrophy rates in dementia with Lewy bodies. <i>Brain</i> , <b>2016</b> , 139, 2740-2750	11.2	51
188	Abnormalities of the executive control network in multiple sclerosis phenotypes: An fMRI effective connectivity study. <i>Human Brain Mapping</i> , <b>2016</b> , 37, 2293-304	5.9	21
187	Cognitive impairment in progressive supranuclear palsy-Richardson's syndrome is related to white matter damage. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 31, 65-71	3.6	14
186	Surrogate Markers in Multiple Sclerosis: The Role of Magnetic Resonance Imaging <b>2016</b> , 163-187		
185	A review of recent literature on functional MRI and personal experience in two cases of definite vestibular migraine. <i>Neurological Sciences</i> , <b>2016</b> , 37, 1399-402	3.5	18
184	Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 7, 33-40	4	17
183	Clinical Pre-genetic Screening for Stroke Monogenic Diseases: Results From Lombardia GENS Registry. <i>Stroke</i> , <b>2016</b> , 47, 1702-9	6.7	27

182	Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1506-1508	5	36
181	Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1315-26	5	46
180	Assessing response to interferon- $\beta$ in a multicenter dataset of patients with MS. <i>Neurology</i> , <b>2016</b> , 87, 134-40	6.5	74
179	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , <b>2016</b> , 263, 1727-35	5.5	35
178	Searching for the neural basis of reserve against memory decline: intellectual enrichment linked to larger hippocampal volume in multiple sclerosis. <i>European Journal of Neurology</i> , <b>2016</b> , 23, 39-44	6	23
177	Impaired functional integration in multiple sclerosis: a graph theory study. <i>Brain Structure and Function</i> , <b>2016</b> , 221, 115-31	4	90
176	Noninvasive Neuromodulation in Poststroke Gait Disorders: Rationale, Feasibility, and State of the Art. <i>Neurorehabilitation and Neural Repair</i> , <b>2016</b> , 30, 71-82	4.7	32
175	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , <b>2016</b> , 15, 574-84	24.1	194
174	Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1144-53	5	37
173	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , <b>2016</b> , 15, 373-81	24.1	118
172	Reading, writing, and reserve: Literacy activities are linked to hippocampal volume and memory in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1621-1625	5	14
171	Brain MR Imaging in Patients with Lower Motor Neuron-Predominant Disease. <i>Radiology</i> , <b>2016</b> , 280, 545-555	25.5	28
170	MR Imaging of Brachial Plexus and Limb-Girdle Muscles in Patients with Amyotrophic Lateral Sclerosis. <i>Radiology</i> , <b>2016</b> , 279, 553-61	20.5	23
169	Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis. <i>Multiple Sclerosis International</i> , <b>2016</b> , 2016, 2303857	1.1	13
168	MRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosis. <i>Current Opinion in Neurology</i> , <b>2016</b> , 29, 243-53	7.1	27
167	Progressive ataxia in a natalizumab-treated multiple sclerosis patient: the dark side of JC virus infection. <i>European Journal of Neurology</i> , <b>2016</b> , 23, e39-40	6	1
166	Structural brain correlates of cognitive and behavioral impairment in MND. <i>Human Brain Mapping</i> , <b>2016</b> , 37, 1614-26	5.9	64
165	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 944-51	5.5	63

164	Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 54, 1495-1508	4.3	17
163	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1386-1396	5	83
162	Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report. <i>Journal of the Neurological Sciences</i> , <b>2016</b> , 361, 184-6	3.2	2
161	Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development. <i>Trends in Pharmacological Sciences</i> , <b>2016</b> , 37, 808-810	13.2	11
160	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 189-97	5	37
159	Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 956-9	5	21
158	Differentiation between Subtypes of Primary Progressive Aphasia by Using Cortical Thickness and Diffusion-Tensor MR Imaging Measures. <i>Radiology</i> , <b>2015</b> , 276, 219-27	20.5	20
157	Pharmacogenetic influence of eNOS gene variant on endothelial and glucose metabolism responses to L-arginine supplementation: Post hoc analysis of the L-arginine trial. <i>Metabolism: Clinical and Experimental</i> , <b>2015</b> , 64, 1582-91	12.7	7
156	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. <i>Brain</i> , <b>2015</b> , 138, 3275-86	11.2	63
155	Thrombolysis with rt-PA for an ischemic stroke in boy treated with Fontan operation. <i>Journal of Pediatric Neurology</i> , <b>2015</b> , 09, 497-500	0.2	
154	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. <i>Journal of Neurology</i> , <b>2015</b> , 262, 2466-71	5.5	4
153	Elevated body temperature is linked to fatigue in an Italian sample of relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , <b>2015</b> , 262, 2440-2	5.5	15
152	Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. <i>Journal of Neurology</i> , <b>2015</b> , 262, 2520-7	5.5	36
151	A multimodal neuroimaging study of a case of crossed nonfluent/agrammatic primary progressive aphasia. <i>Journal of Neurology</i> , <b>2015</b> , 262, 2336-45	5.5	19
150	Oral corticosteroids for multiple sclerosis relapse. <i>Lancet, The</i> , <b>2015</b> , 386, 937-9	4.0	5
149	Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , <b>2015</b> , 289, 62-7	3.5	13
148	Relapses in patients treated with fingolimod after previous exposure to natalizumab. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 786-90	5	20
147	Following the Spreading of Brain Structural Changes in Alzheimer's Disease: A Longitudinal, Multimodal MRI Study. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 47, 995-1007	4.3	15

146	Ceruloplasmin functional changes in Parkinson's disease-cerebrospinal fluid. <i>Molecular Neurodegeneration</i> , <b>2015</b> , 10, 59	19	26
145	Brain structural and functional connectivity in Parkinson's disease with freezing of gait. <i>Human Brain Mapping</i> , <b>2015</b> , 36, 5064-78	5.9	97
144	Hippocampal-DMN disconnectivity in MS is related to WM lesions and depression. <i>Human Brain Mapping</i> , <b>2015</b> , 36, 5051-63	5.9	41
143	The Communication of Multiple Sclerosis Diagnosis: The Patients' Perspective. <i>Multiple Sclerosis International</i> , <b>2015</b> , 2015, 353828	1.1	5
142	White Matter Degeneration in Atypical Alzheimer Disease. <i>Radiology</i> , <b>2015</b> , 277, 162-72	20.5	37
141	White matter microstructure abnormalities in pediatric migraine patients. <i>Cephalalgia</i> , <b>2015</b> , 35, 1278-86	6.1	27
140	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1013-24	5	181
139	Excitatory deep repetitive transcranial magnetic stimulation with H-coil as add-on treatment of motor symptoms in Parkinson's disease: an open label, pilot study. <i>Brain Stimulation</i> , <b>2014</b> , 7, 297-300	5.1	27
138	Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. <i>Journal of Neurology</i> , <b>2014</b> , 261, 267-76	5.5	100
137	Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , <b>2014</b> , 13, 247-56	24.1	363
136	Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 147-55	5	72
135	Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 862-70	5	9
134	Resting state functional connectivity alterations in primary lateral sclerosis. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 916-25	5.6	30
133	Multiple sclerosis progression is not associated with birth timing in Italy. <i>Journal of the Neurological Sciences</i> , <b>2014</b> , 346, 194-6	3.2	1
132	Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. <i>Neurology</i> , <b>2014</b> , 83, 1432-8	6.5	78
131	Autologous bone marrow transplantation for the treatment of multiple sclerosis. <i>Current Neurology and Neuroscience Reports</i> , <b>2014</b> , 14, 478	6.6	22
130	Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. <i>Journal of Neurology</i> , <b>2014</b> , 261, 1781-8	5.5	20
129	Peripheral nerve morphogenesis induced by scaffold micropatterning. <i>Biomaterials</i> , <b>2014</b> , 35, 4035-4045	5.6	31

128	Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , <b>2014</b> , 13, 977-86	24.1	208
127	Defining the clinical course of multiple sclerosis: the 2013 revisions. <i>Neurology</i> , <b>2014</b> , 83, 278-86	6.5	1632
126	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. <i>Lancet Neurology, The</i> , <b>2014</b> , 13, 257-67	24.1	156
125	Disrupted brain connectome in semantic variant of primary progressive aphasia. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 2646-2655	5.6	59
124	Intrahemispheric and interhemispheric structural network abnormalities in PLS and ALS. <i>Human Brain Mapping</i> , <b>2014</b> , 35, 1710-22	5.9	64
123	Efficacy of subcutaneous interferon $\beta$ 1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 647-53	5.5	16
122	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 851-8	5.5	84
121	Position and practical use of fingolimod in Europe. <i>Clinical and Experimental Neuroimmunology</i> , <b>2014</b> , 5, 19-33	0.4	6
120	Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 705-16	5	237
119	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , <b>2014</b> , 3, 147-55	4	43
118	Deep repetitive transcranial magnetic stimulation with H-coil on lower limb motor function in chronic stroke: a pilot study. <i>Archives of Physical Medicine and Rehabilitation</i> , <b>2014</b> , 95, 1141-7	2.8	32
117	Clinical and MRI correlates of disease progression in a case of nonfluent/agrammatic variant of primary progressive aphasia due to progranulin (GRN) Cys157LysfsX97 mutation. <i>Journal of the Neurological Sciences</i> , <b>2014</b> , 342, 167-72	3.2	12
116	Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. <i>Journal of Neurology</i> , <b>2013</b> , 260, 2472-80	5.5	31
115	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. <i>Journal of Neurology</i> , <b>2013</b> , 260, 2023-32	5.5	72
114	Treatment of cognitive impairment in multiple sclerosis: position paper. <i>Journal of Neurology</i> , <b>2013</b> , 260, 1452-68	5.5	161
113	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. <i>Journal of Neurology</i> , <b>2013</b> , 260, 1136-46	5.5	33
112	Brain atrophy and lesion load predict long term disability in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2013</b> , 84, 1082-91	5.5	209
111	Italian multicentre observational study of the prevalence of CCSVI in multiple sclerosis (CoSMo study): rationale, design, and methodology. <i>Neurological Sciences</i> , <b>2013</b> , 34, 1297-307	3.5	14

110	Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1084-94	5	39
109	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1074-83	5	72
108	Disease-modifying treatments for progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1428-36	5	38
107	Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 123-36	4	21
106	Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex. <i>Neuropharmacology</i> , <b>2013</b> , 67, 1-7	5.5	34
105	Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm: a nerve conduction study. <i>Neurological Sciences</i> , <b>2013</b> , 34, 209-15	3.5	4
104	Extramotor damage is associated with cognition in primary lateral sclerosis patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e82017	3.7	28
103	Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. <i>Lancet Neurology, The</i> , <b>2012</b> , 11, 33-41	24.1	153
102	Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2012</b> , 1, 49-54	4	21
101	Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. <i>Annals of Neurology</i> , <b>2012</b> , 72, 610-24	9.4	201
100	Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. <i>American Journal of Pathology</i> , <b>2012</b> , 180, 267-74	5.8	115
99	Placebo-controlled trial of oral laquinimod for multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1000-9	59.2	290
98	Sturge-Weber syndrome with an unusual onset in the sixth decade: a case report. <i>Neurological Sciences</i> , <b>2012</b> , 33, 949-50	3.5	4
97	Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRibine Tablets treating multiple sclerosis orally) study. <i>Multiple Sclerosis Journal</i> , <b>2011</b> , 17, 578-93	5	88
96	A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. <i>European Journal of Neurology</i> , <b>2011</b> , 18, 1122-31	6	276
95	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 520-9	24.1	178
94	Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. <i>Neurological Sciences</i> , <b>2011</b> , 31 Suppl 3, 299-302	3.5	46
93	Natalizumab: state of the art and open questions. <i>Neurological Sciences</i> , <b>2011</b> , 31 Suppl 3, 313-5	3.5	1



92	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. <i>Neurological Sciences</i> , <b>2011</b> , 32, 351-8	3.5	15
91	A fatal case of Churg-Strauss syndrome presenting with acute polyneuropathy mimicking Guillain-Barré syndrome. <i>Neurological Sciences</i> , <b>2011</b> , 32, 937-40	3.5	9
90	Randomized trial of oral teriflunomide for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1293-303	59.2	662
89	Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2011</b> , 82, 1344-50	5.5	62
88	Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 402-15	59.2	1686
87	The contribution of MRI in assessing cognitive impairment in multiple sclerosis. <i>Neurology</i> , <b>2010</b> , 75, 2121-8	6.5	135
86	A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 416-26	59.2	591
85	Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 197-207	5	134
84	Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 1360-6	5	52
83	Neurophysiological correlates of cognitive disturbances in multiple sclerosis. <i>Neurological Sciences</i> , <b>2010</b> , 31, S249-53	3.5	15
82	Effects of disease modifying treatments on cognitive dysfunction in multiple sclerosis. <i>Neurological Sciences</i> , <b>2010</b> , 31, S261-4	3.5	18
81	Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. <i>Annals of Neurology</i> , <b>2010</b> , 68, 409-11	9.4	35
80	A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. <i>Neurology</i> , <b>2009</b> , 73, 1842-8	6.5	65
79	250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. <i>Lancet Neurology</i> , <b>2009</b> , 8, 889-97	24.1	338
78	Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , <b>2009</b> , 66, 513-20	9.4	109
77	Corpus callosum damage and cognitive dysfunction in benign MS. <i>Human Brain Mapping</i> , <b>2009</b> , 30, 2656-66	6.6	82
76	Mitoxantrone: benefits and risks in multiple sclerosis patients. <i>Neurological Sciences</i> , <b>2009</b> , 30 Suppl 2, S167-70	3.5	59
75	Treatment of multiple sclerosis: role of natalizumab. <i>Neurological Sciences</i> , <b>2009</b> , 30 Suppl 2, S155-8	3.5	21

74	Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , <b>2009</b> , 286, 109-13	3.2	22
73	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2009</b> , 374, 1503-11	4.0	475
72	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet, The</i> , <b>2008</b> , 371, 2085-92	4.0	236
71	Clinically isolated syndrome: the rationale for early treatment. <i>Nature Clinical Practice Neurology</i> , <b>2008</b> , 4, 234-5		16
70	Definition of responder: introduction. <i>Neurological Sciences</i> , <b>2008</b> , 29 Suppl 2, S209-10	3.5	1
69	Induction vs. escalating therapy in multiple sclerosis: practical implications. <i>Neurological Sciences</i> , <b>2008</b> , 29 Suppl 2, S253-5	3.5	30
68	Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage. <i>Journal of Cell Science</i> , <b>2006</b> , 119, 3981-93	5.3	149
67	Oral fingolimod (FTY720) for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 1124-40	59.2	877
66	MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. <i>Journal of the Neurological Sciences</i> , <b>2006</b> , 245, 111-6	3.2	60
65	Early treatment. <i>Neurological Sciences</i> , <b>2006</b> , 27 Suppl 1, S8-12	3.5	11
64	Understanding fatigue in multiple sclerosis: new insights in causes and assessment. <i>Neurological Sciences</i> , <b>2006</b> , 27, s304-s306	3.5	4
63	Italian Multiple Sclerosis Database Network. <i>Neurological Sciences</i> , <b>2006</b> , 27 Suppl 5, S358-61	3.5	14
62	Imaging Spinal Cord Damage in Multiple Sclerosis <b>2005</b> , 15, 297-304		11
61	Evidence for use of glatiramer acetate in multiple sclerosis. <i>Lancet Neurology, The</i> , <b>2005</b> , 4, 75-6; discussion 76-7	24.1	7
60	Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. <i>Neurology</i> , <b>2004</b> , 62, 1432-4	6.5	106
59	Multiple sclerosis: pseudotumoral forms. <i>Neurological Sciences</i> , <b>2004</b> , 25 Suppl 4, S374-9	3.5	33
58	Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. <i>Human Brain Mapping</i> , <b>2004</b> , 21, 108-17	5.9	85
57	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2004</b> , 364, 1489-96	4.0	215

56	A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. <i>Journal of Neurology</i> , <b>2002</b> , 249, 1370-7	5.5	123
55	Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. <i>Journal of the Neurological Sciences</i> , <b>2002</b> , 195, 103-9 <sup>2</sup>	3.2	185
54	Neurophysiology <b>2002</b> , 25-33		
53	Physiopathology and treatment of fatigue in multiple sclerosis. <i>Journal of Neurology</i> , <b>2001</b> , 248, 174-9	5.5	137
52	European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. <i>Annals of Neurology</i> , <b>2001</b> , 49, 290-297	9.4	624
51	Effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis. <i>Annals of Neurology</i> , <b>2001</b> , 49, 415-416	9.4	27
50	The role of non-conventional MR techniques to study multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , <b>2001</b> , 186 Suppl 1, S3-9	3.2	11
49	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. <i>Lancet, The</i> , <b>2001</b> , 357, 1576-82	4.0	884
48	European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis <b>2001</b> , 49, 290		19
47	European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. <i>Annals of Neurology</i> , <b>2001</b> , 49, 290-7	9.4	170
46	Whole brain volume changes in patients with progressive MS treated with cladribine. <i>Neurology</i> , <b>2000</b> , 55, 1714-8	6.5	114
45	Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. <i>Journal of Neurology</i> , <b>2000</b> , 247, 960-5	5.5	46
44	MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. <i>Journal of Neurology</i> , <b>2000</b> , 247, 506-9	5.5	97
43	Prognosis-modifying therapy in multiple sclerosis. <i>Neurological Sciences</i> , <b>2000</b> , 21, S893-9	3.5	6
42	Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study. <i>Neurology</i> , <b>2000</b> , 55, 940-6	6.5	130
41	Electrophysiological correlates of dementia. <i>Supplements To Clinical Neurophysiology</i> , <b>2000</b> , 53, 331-6		2
40	Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2000</b> , 69, 192-8 <sup>5.5</sup>	5.5	77
39	Assessment of the damage of the cerebral hemispheres in MS using neuroimaging techniques. <i>Journal of the Neurological Sciences</i> , <b>2000</b> , 172 Suppl 1, S63-6	3.2	17

38	Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. <i>Neurology</i> , <b>1999</b> , 52, 588-94	6.5	226
37	Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis. <i>Magnetic Resonance Imaging</i> , <b>1999</b> , 17, 985-8	3.3	7
36	A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. <i>Journal of Neurology</i> , <b>1999</b> , 246, 97-106	5.5	7
35	Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , <b>1999</b> , 171, 130-4	3.2	13
34	A multiparametric MRI study of frontal lobe dementia in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>1999</b> , 171, 135-44	3.2	40
33	Introduction. <i>Neurological Sciences</i> , <b>1999</b> , 20, S227-8	3.5	
32	Neurophysiological imaging techniques in dementia. <i>Neurological Sciences</i> , <b>1999</b> , 20, S265-9	3.5	9
31	The Italian multicentre study on the prevalence of distal symmetric polyneuropathy: correlation between clinical variables and nerve conduction parameters. Italian Diabetic Neuropathy Committee. <i>Electroencephalography and Clinical Neurophysiology Supplement</i> , <b>1999</b> , 50, 546-52		1
30	Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients. <i>Annals of Neurology</i> , <b>1998</b> , 43, 340-9	9.4	41
29	Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. <i>Annals of Neurology</i> , <b>1998</b> , 43, 809-14	9.4	283
28	Event-related desynchronization to contingent negative variation and self-paced movement paradigms in Parkinson's disease. <i>Movement Disorders</i> , <b>1998</b> , 13, 653-60	7	53
27	Neuromyotonia, systemic lupus erythematosus and acetylcholine-receptor antibodies. <i>Journal of Neurology</i> , <b>1998</b> , 245, 182-5	5.5	3
26	Treatment of chronic inflammatory demyelinating polyneuropathy. <i>Italian Journal of Neurological Sciences</i> , <b>1998</b> , 19, 261-9		1
25	EEG correlates of cognitive impairment in MS. <i>Italian Journal of Neurological Sciences</i> , <b>1998</b> , 19, S413-S417		2
24	Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. <i>Neurology</i> , <b>1998</b> , 50, 1601-8	6.5	230
23	Neurophysiological and cognitive markers of disease evolution in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>1998</b> , 4, 260-5	5	23
22	Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. <i>American Journal of Neuroradiology</i> , <b>1998</b> , 19, 223-9	4.4	47
21	Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune-mediated neuropathies. <i>Multiple Sclerosis Journal</i> , <b>1997</b> , 3, 93-7	5	5

20	Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. <i>Brain</i> , <b>1997</b> , 120 ( Pt 11), 2059-69	11.2	832
19	Axonal neuropathy associated with interferon-alpha treatment for hepatitis C: HLA-DR immunoreactivity in Schwann cells. <i>Acta Neuropathologica</i> , <b>1997</b> , 94, 504-8	14.3	19
18	Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. <i>Journal of Neurology</i> , <b>1997</b> , 244, 266-70	5.5	148
17	Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. <i>Neurology</i> , <b>1996</b> , 46, 379-84	6.5	110
16	Quantitative assessment of MRI lesion load in multiple sclerosis. A comparison of conventional spin-echo with fast fluid-attenuated inversion recovery. <i>Brain</i> , <b>1996</b> , 119 ( Pt 4), 1349-55	11.2	147
15	Functional basis of memory impairment in multiple sclerosis: a [18F]FDG PET study. <i>NeuroImage</i> , <b>1996</b> , 4, 87-96	7.9	117
14	Interferon beta treatment in multiple sclerosis: the European clinical trials. <i>Multiple Sclerosis Journal</i> , <b>1996</b> , 1, 317-20	5	
13	Brain MRI follow-up of patients with persistent isolated optic neuritis. <i>European Journal of Neurology</i> , <b>1996</b> , 3, 36-39	6	2
12	A spinal cord MRI study of benign and secondary progressive multiple sclerosis. <i>Journal of Neurology</i> , <b>1996</b> , 243, 502-5	5.5	108
11	Clinical utility of evoked potentials in patients infected with human immunodeficiency virus. <i>Electroencephalography and Clinical Neurophysiology Supplement</i> , <b>1996</b> , 46, 85-93		2
10	Neurophysiologic studies and cognitive function in congenital hypothyroid children. <i>Pediatric Research</i> , <b>1995</b> , 37, 736-40	3.2	15
9	A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. <i>Neurology</i> , <b>1995</b> , 45, 478-82	6.5	332
8	Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>1995</b> , 132, 222-7	3.2	150
7	Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>1993</b> , 115 Suppl, S66-73	3.2	76
6	Brain stem magnetic resonance imaging and evoked potential studies of symptomatic multiple sclerosis patients. <i>European Neurology</i> , <b>1993</b> , 33, 232-7	2.1	25
5	Heterogeneity of autoantibodies in stiff-man syndrome. <i>Annals of Neurology</i> , <b>1993</b> , 34, 57-64	9.4	106
4	Correlation between multimodal evoked potentials and magnetic resonance imaging in multiple sclerosis. <i>Journal of Neurology</i> , <b>1989</b> , 236, 4-8	5.5	37
3	Visual evoked potentials in diabetic teen-agers: influence of metabolic control and relationship with peripheral neuropathy. <i>Metabolic, Pediatric, and Systemic Ophthalmology</i> , <b>1986</b> , 9, 85-7		6

2	Human-Centered Design Strategies for Device Selection in mHealth Programs: Development of a Novel Framework and Case Study (Preprint)	1
1	Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19 (Preprint)	4